Vyome (NASDAQ:HIND) & Longevity Health (NASDAQ:XAGE) Head-To-Head Analysis

Vyome (NASDAQ:HIND) and Longevity Health (NASDAQ:XAGE) are both small-cap manufacturing companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for Vyome and Longevity Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	0	0	2	0	3.00
Longevity Health	0	0	0	0	0.00

Vyome presently has a consensus target price of $15.00, indicating a potential upside of 184.09%. Given Vyome’s stronger consensus rating and higher possible upside, research analysts plainly believe Vyome is more favorable than Longevity Health.

Profitability

This table compares Vyome and Longevity Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vyome	-69.71%	-216.95%	-69.42%
Longevity Health	-682.67%	N/A	-261.90%

Valuation and Earnings

This table compares Vyome and Longevity Health”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$8.01 million	2.41	-$7.13 million	($433.08)	-0.01
Longevity Health	$1.05 million	0.98	-$10.37 million	N/A	N/A

Vyome has higher revenue and earnings than Longevity Health.

Risk and Volatility

Vyome has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Longevity Health has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.

Institutional & Insider Ownership

22.1% of Vyome shares are held by institutional investors. Comparatively, 24.2% of Longevity Health shares are held by institutional investors. 33.0% of Vyome shares are held by company insiders. Comparatively, 29.0% of Longevity Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Vyome beats Longevity Health on 10 of the 12 factors compared between the two stocks.

About Vyome

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

About Longevity Health

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.